Agreed. I'd rather see NWBO engage with MHRA to argue for the best possible label than just accept whatever the regulators deem is expedient for approval. A few extra weeks of negotiation to secure a full approval or a broader label is what we need to drive commercial and investor value and knock down the bear case that the trial results were some how flawed. Im hanging on what George said "Stay tuned for MORE POSITIVE DEVELOPMENTS IN THE NEXT FEW WEEKS AND MONTHS" I think he means approval and everything that comes after it.
Market Data 
Markets 
AI
